IACTA Pharmaceuticals was established to develop and commercialize innovative eyecare products. We’re dedicated to treating diseases, advancing technology and improving patient outcomes. Our lead investigational product, NM133, is a nano-enabled form of cyclosporine A which is being developed for the treatment of dry eye.

AstraZeneca Pharmaceuticals. SHE Coordinator · 2005 to 2010 · Södertälje, Sweden. AstraZeneca Pharmaceuticals. first line manager · 2000 to Alea iacta est

See the full list at Craft. Explore IACTA Pharmaceuticals's investment information, scientific platforms, therapeutic approaches, indications and more here! IACTA Pharmaceuticals | 119 followers on LinkedIn. Delivering cutting-edge eye care products. | Our goal is to vastly improve patient care and outcomes by bringing innovative eye care technology IACTA Pharmaceuticals and Pharmaleads announced they have entered into licensing agreements with IACTA acquiring global rights to Pharmaleads’ Dual Enkephalinase Inhibitors (DENKI), a novel class of non-opioid compounds for the treatment of acute and chronic ocular pain.

Iacta pharmaceuticals

Färögatan 33. 164 51, KISTA Alea Iacta Est AB. 0707307961. Artillerigatan 38. 114 45, STOCKHOLM Hygieia Biological Laboratories.

Lung Therapeutics. Actuate Therapeutics.

Jan 23, 2017 IACTA Pharmaceuticals Inc. has acquired the North American rights to develop and commercialize NM133, which is designed to help treat dry

For more About IACTA Pharmaceuticals, Inc. IACTA is an ophthalmic focused pharmaceutical company led by former top executives from one of the leading eye care companies in the world, Allergan. 2021-01-07 Explore IACTA Pharmaceuticals's investment information, scientific platforms, therapeutic approaches, indications and more here!

IACTA Pharmaceuticals and Zhaoke Ophthalmology agree to co-develop novel eye treatments July 30, 2020; New licensing agreement accelerates the development of IACTA Pharmaceuticals’ novel dry eye disease and allergic conjunctivitis treatments on China and Southeast Asia July 28, 2020

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--IACTA Pharmaceuticals, Inc., a privately held pharmaceutical company, has acquired the North American rights to develop and commercialize NM133, an investigational medicine designed to help treat dry eye, from its developer, Nanomerics, Ltd. “We are enthusiastic about partnering with Nanomerics and are grateful that they have placed their trust in us IACTA Pharmaceuticals and Pharmaleads announced they have entered into licensing agreements with IACTA acquiring global rights to Pharmaleads’ Dual Enkephalinase Inhibitors (DENKI), a novel class of non-opioid compounds for the treatment of acute and chronic ocular pain. IACTA Pharmaceuticals is a company focused on the development of therapeutics for the application in ophthalmology. Its product pipeline includes Syk kinase inhibitor, broad-spectrum ocular antibiotic, and topical cyclosporine for dry eye. IACTA Pharmaceuticals, located in Newport Beach, California, is a privately held company focused on bringing the latest technology to the healthcare industry and eyecare specifically. For more About IACTA Pharmaceuticals, Inc. IACTA is an ophthalmic focused pharmaceutical company led by former top executives from one of the leading eye care companies in the world, Allergan. 2021-01-07 Explore IACTA Pharmaceuticals's investment information, scientific platforms, therapeutic approaches, indications and more here!

Its product pipeline includes Syk kinase inhibitor, broad-spectrum ocular antibiotic, and topical cyclosporine for dry eye.
Amiralsstaden

IACTA Pharmaceuticals and Pharmaleads to Develop the World’s First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain. Source: IACTA Pharmaceuticals About IACTA Pharmaceuticals, Inc. IACTA Pharmaceuticals, located in Newport Beach, California, is a privately held company focused on bringing the latest technology to the healthcare industry and eyecare specifically.

Mark For: OLIVIA ISABELLA™ trademark registration is intended to cover the category of ophthalmic solutions and preparations. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by IACTA PHARMACEUTICALS IACTA Pharmaceuticals partnered with UK-based Nanomerics, Ltd., a global leader in pharmaceutical research and the developer of MET. IACTA has an exclusive license for NM133, cyclosporine with MET, in North America. "This award recognizes the significant role MET nanotechnology can play in novel methods of drug delivery. 2021-03-31 IACTA Pharmaceuticals, Inc., a privately held pharmaceutical company, has acquired the North American rights to develop and commercialize NM133, an investigational medicine designed to help treat dry eye, from its developer, Nanomerics, Ltd. Nanomerics is a privately held, UK-based, research-stage company with a proprietary Molecular Envelope Technology (MET) licensed from University College IACTA Pharmaceuticals is an R&D focused company that is creating innovative treatment-opportunities in the ever-growing industry of ophthalmology and eye care.
Carmen cd

matte direkt 7 facit
affarsverket svenska kraftnat
e tjanster 1177
birgitta lindqvist
gu lediga stipendier
personligt träningsprogram online

Aug 27, 2020 Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", IACTA Pharmaceuticals, Inc. ("IACTA"), a U.S.-based ophthalmology

We’re dedicated to treating diseases, advancing technology and improving patient outcomes.